All articles by
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic today announced the award of a contract valued at EUR 65 million to supply its MVA-BN smallpox vaccine…
Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients
Huma Therapeutics, a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany, a leading science and technology…
Pfizer’s Beqvez gets FDA approval for adults with haemophilia B
Pfizer has received the US Food and Drug Administration (FDA) approval for Beqvez (fidanacogene elaparvovec-dzkt) to treat certain adult patients…
Advent International to invest $300m in India`s Apollo 24|7
Private equity firm Advent International has unveiled its plans to invest INR24.75bn ($300m) in Apollo HealthCo (Apollo 24|7 or AHL),…
Perrigo to divest HRA Pharma Rare Diseases business to Esteve for €275m
Perrigo, a provider of consumer self-care products, has agreed to divest its HRA Pharma Rare Diseases business to Esteve Healthcare…
FDA approves Freedom Biosciences’ IND for FREE001 in TRD patients
Freedom Biosciences has received the US Food and Drug Administration (FDA) approval of an investigational new drug (IND) application for…
Jemperli gets FDA priority review for expanded indication in endometrial cancer
The US Food and Drug Administration (FDA) has granted priority review to GSK’s supplemental biologics license application (sBLA) to expand…
FDA authorises Utility Therapeutics’ Pivya tablets for UTIs
The US Food and Drug Administration (FDA) has authorised the use of Utility Therapeutics’ Pivya (pivmecillinam) tablets in female adults…
Travere and CSL Vifor get conditional EC approval for Filspari in IgAN
Travere Therapeutics and CSL Vifor have received conditional marketing authorisation (CMA) from the European Commission (EC) for Filspari (sparsentan) to…
Incyte to acquire Escient Pharmaceuticals for over $750m
Incyte has agreed to acquire Escient Pharmaceuticals and its two potential first-in-class oral Mas-related G protein-coupled receptor (MRGPR) antagonists in…